Risk to staff after unprotected bronchoscopy on cavitary, highly infectious TB
Bold, direct recommendation: The attack rate for staff after an unprotected bronchoscopy on a cavitary, AFB-strongly positive MTB case is high enough to warrant urgent post-exposure management, with an estimated transmission risk per close, room‑present staff member in the range of roughly 10–30% in poorly ventilated settings without respirators, and the highest risk concentrated among those in closest proximity to the airway during the procedure 1, 2.
Rationale and best evidence
- Guidelines emphasize bronchoscopy as a high‑risk, aerosol‑generating exposure for pulmonary TB; staff closest to the patient during bronchoscopy have the highest conversion rates; N95 or powered air-purifying respirators should be used; absence of respirators markedly increases risk [1–1].
- The most recent, highest‑quality systematic review across healthcare settings (post‑modern ventilation era) estimates transmission at 3.8% overall; however, risk rises substantially without respirators (≈12.1%) and with poor/no negative pressure (≈33.6%). Short exposures (<8 hours) rarely transmit unless ventilation is poor; bronchoscopy is an intense short exposure with heavy aerosols and often suboptimal ventilation, pushing risk toward the higher end when unprotected 2.
- Cavitary disease and strong AFB positivity indicate high bacillary burden and infectiousness; post‑bronchoscopy cough/sputum often increases contagiousness transiently 3.
Practical numbers to use now (assume no masks, typical bronchoscopy room ventilation uncertain)
- Close, room‑present staff within a few meters of the airway (bronchoscopist, assistant, RT/nurse at bedside): 10–30% may be infected per exposure episode, higher if ventilation was poor or negative pressure absent [1–1,2].
- Other staff briefly in room but not at bedside: 5–10%, modulated by time spent and room air changes 2.
- Outside room or passing entry only: low (<1–5%), unless door was open with poor ventilation 2.
- Example estimation for planning: if 5 bedside staff were unmasked in a non–negative‑pressure room, anticipate 1–2 latent TB infections on average, potentially more with prolonged room presence 2.
Immediate actions to reduce morbidity, mortality, and quality‑of‑life impact
- Identify and stratify exposed staff by proximity and time in room; prioritize those at the bedside and present throughout scope insertion/suctioning [1–1].
- Baseline TB testing now (IGRA preferred) and repeat at 8–10 weeks; offer window‑period management per local policy for very high‑risk exposures [1–1].
- Prompt evaluation for symptoms; low threshold CXR if symptomatic or immunocompromised.
- For high‑risk exposures, discuss latent TB infection treatment if conversion occurs; this prevents progression and preserves QOL and survival.
- Audit room ventilation; confirm negative pressure and ≥12–14 ACH; remediate before next procedure [1–1].
- Reinforce PPE: at minimum N95; PAPRs preferred for suspected/known TB bronchoscopy [1–1].
Nuances, pitfalls, and how to avoid them
- Pitfall: Assuming short procedure time equals low risk. Bronchoscopy concentrates aerosols at source; proximity trumps duration here—risk is substantial without respirators [1–1,2].
- Pitfall: Ignoring ventilation. Transmission spikes without negative pressure/adequate ACH; confirm engineering controls [1–1,2].
- Pitfall: Underestimating infectiousness post‑procedure—post‑bronchoscopy sputum often becomes smear positive, reflecting heightened infectivity; ensure strict isolation after the procedure too 3.
- Device reprocessing failures can transmit TB between patients; verify high‑level disinfection/sterilization compliance immediately 4.
Why this estimate
- Guideline consensus marks bronchoscopy on TB as high‑risk and mandates respirators; historical data show highest conversions among bronchoscopic proximity staff [1–1].
- The most recent, broad systematic review quantifies risk increases specifically tied to lack of respirators and poor ventilation; applying those strata to a cavitary, AFB‑strong case justifies the 10–30% bedside estimate and guides decisive post‑exposure actions to protect morbidity, mortality, and QOL 2.